Veterinary Healthcare Industry Overview

The anesthesia disposables market consists of sales of anesthesia disposables and related services. These disposables include onetime use anesthesia circuits, anesthesia masks, sample lines, filters/Heat & Moisture Exchangers (HMEs), breathing bag, endotracheal tubes, and laryngeal masks. The Anesthesia disposables are easy to use and portable devices. To a large extent, they have replaced the reusable ones and are largely used to the whole body or a targeted part of the body during tests and surgical operations so that the patient does not experience the pain and other sensations. The global anesthesia disposables market is expected to grow from $0.47 billion in 2020 to $0.52 billion in 2021 at a compound annual growth rate (CAGR) of 10.6%. The change in growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The market is expected to reach $0.64 billion in 2025 at a CAGR of 5.3%. The increase in aging population leads to increased surgeries driving the anesthesia disposable market. Increasing life expectancies paired with age-related comorbidities have resulted in the growth of elderly population who undergo surgeries. The prevalence of cardiovascular disease, arthritis, thyroid disease, and emphysema is steadily increasing, which is proportionally increasing the number of surgeries coupled with growing prevalence of diseases. These diseases are found mainly in elderly people, which is increasing the consumption of anesthesia disposables as they are widely used in the surgical procedures and is driving the market in the forecast period. Lack of trained anesthesiologists is restraining the market. Anesthetist plays a very vital role in patient's care during and post any surgery or operation. They acquire the ability to offer a premium level care to their patients. As with the increase in number of patients especially for surgery and operations across the globe, the demand of skilled and trained anesthetists also increases. To meet rising patient demand for anesthesia services, countries are facing critical shortage of skilled and trained anesthetists. For example, Centre for Workforce Intelligence, a unit of UK NHS staffing agency Health Education England stated that according to their study, the demand for anesthetic services would grow by 25% by 2033, and would require the number of anesthetists to grow by 300 a year. As reported in a study conducted by the American Association of Medical Colleges (AAMC), a shortfall of 33,800 to 72,700 physicians across the specialties is expected by 2030.Thus there is a significant gap in the requirement of trained anesthesiologist across country which is likely to hinder the growth of anesthesia disposables market. The demand for cuffed endotracheal tubes (ETTs) in the pediatrics is growing as compared to the uncuffed ETTs. During pediatric anesthesia, general endotracheal intubation is commonly performed for airway management and positive pres-sure ventilation. Traditionally, uncuffed endo-tracheal tubes (ETTs) are recommended for children up to eight years old. But due to the major disadvantages of the uncuffed ETTs such as an increase in air leakage around the tube, making it difficult to ensure that the child is breathing adequate amounts of oxygen. In addition, the measurement of tidal volume is also compromised. Uncuffed ETTs also allow waste anesthetic gases to escape, contributing significantly to operating room contamination and rendering the anesthetic procedure more expensive. Therefore, the trend is towards increasing usage of cuffed ETTs for the pediatric procedures. According to American Association of Nurse Anesthetists, facilities should select disposables registered with the U.S. Environmental Protection Agency (EPA) and follow manufacturer recommendations regarding use, exposure time, and disposal. Also, they should discard disposable single-use devices in a biohazardous bag/container (e.g., breathing circuits, airway devices, orogastric tubes) immediately after use. Major players in the market are Ambu A/S (Denmark), Medline Industries, Inc. (USA), Smiths Medical, (USA), Teleflex, Inc. (USA) and Vyaire Medical Inc. (USA). The countries covered in the global anesthesia disposables market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, Australia. The regions covered in the global anesthesia disposables market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global anesthesia disposables market is segmented - 1) By Product: Anesthesia Breathing Circuits, Endotracheal Tubes, Anesthesia Gas Masks, Laryngeal Mask Airway 2) By End Users: Hospitals, Clinics, Home Care Settings, Other End Users 3) By Patient Group: Neonatal, Adult, Pediatric

The medical feed additives market consists of sales of medical feed additives and related services in order to prepare complete food for animals. Medical feed additives help improve the nutritional content and quality of feed, results in better productivity, and prevents animals from diseases. Medical feed additives industry includes companies that produce animal feed additives such as vitamins and probiotic, preservatives, antioxidants, digestibility enhancers, gut flora stabilizers and others. The global medical feed additives market is expected to grow from $11.2 billion in 2020 to $13.3 billion in 2021 at a compound annual growth rate (CAGR) of 18.8%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $16.65 billion in 2025 at a CAGR of 5.8%. Increase in prevalence of diseases among animals is driving the growth of the medicated feed additives market According to the estimates from report by Animal and Plant Health Agency, a total of 3289 number of new TB herd incidents were detected in England. A new herd incident is a case of bovine TB that occurs as a result of a herd or individual animal test performed in an officially TB-free (OTF) herd during the study period. Bovine tuberculosis is a chronic disease which usually affects animals such as cattle, but it can affect all mammals causing illness, coughing and eventual death. Moreover, according to the reports the herd incidence rate in England for the 12 months to end September 2020 was 9.4.The additives help prevent animals from diseases alongside increasing the nutrition level of the feed thereby increasing demand for feed additives. The overuse and inappropriate use of antibiotics in medical feed additives impacts the health of individuals consuming the animal meat or other related products. Moreover, the health of the animal consuming the feed may also be adversely affected by the antibiotics added to the feed as the excess additive reduces the natural immunity of the animal and increases susceptibility of the livestock to infections. For instance, on July 1 2020, the Ministry of Agriculture and Rural Affairs in China, under Announcement No. 194 banned the production of commercial feed with medicated feed additives (excluding traditional Chinese medicine) for growth promoting purposes The negative effects of additives on human health caused due to overuse of feed additives in animals will restrain the growth of the market. Companies in the medical feed additives market are introducing new feed medicated additives formed as a result of combination of two or more medicated feed additives. More than 70% of manufacturers are now using more than one feed additive in animal feed to increase the efficiency of the product. For instance, Zoetis, a global health company got the approval for its Cyden and Lincomix combination feed additive from the FDA (Food and Drug Administration) and is proposed to be used as medicated feed additive for poultry. Also, FDA approved combination of Zoetis’ feed additives ACTOGAIN 45 (ractopamine hydrochloride) and ENGAIN (ractopamine hydrochloride) that makes more lean muscle and less fat while optimizing feed efficiency. The medical feed additives market is regulated by government agencies which lay down regulations to be followed by all the manufacturers of veterinary medicines. For instance, the Veterinary Medicines Regulations (VMR) 2013 makes provision for the authorization, manufacturing and classification of veterinary products including medicated feed additives. The Schedule 5 under EU guidelines covers medicated feeding stuffs and specified feed additives which specifies guidance to both manufactures and suppliers of veterinary medicines for incorporating it into animal feed as well as to veterinary surgeons, animal keepers and other members involved in the use of veterinary medicines and SFAs(Specified Feed Additives)in animal feeding stuffs. In February 2019, Archer Daniels Midland Company (ADM), an American global food processing and commodities trading company acquired Neovia for $1.74 billion (€1.544 billion). This acquisition helps ADM to become a global leader in animal nutrition products and services with Neovia adding a wide range of products to the former company’s portfolio including pet care, additives, aquaculture, and livestock feed which would in turn boost the growth of the company. Neovia is headquartered in France was established in 1954 and manufactures and distributes various biologically degradable disinfectants along with feed additives for plants and animals. Major players in the market are Zoetis Inc., Cargill, CHS Inc., Purina Animal Nutrition (Land O' Lakes) and Archer Daniels Midland Company. The countries covered in the global medical feed additives market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, Australia. The regions covered in the global medical feed additives market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global medical feed additives market is segmented - 1) By Type: Antioxidants, Antibiotics, Probiotics & prebiotics, Enzymes, Amino acids 2) By Livestock: Ruminants, Poultry, Swine, Aquaculture 3) By Mixture Type: Supplements, Concentrates, Premix Feeds, Base Mixes 4) By Class type: Type A, Type B, Type C

The veterinary anesthesia equipment market consists of sales of veterinary anesthesia equipment and related services. Veterinary anesthesia equipment is used to deliver anesthetic agents into patients' bodies to prevent the pain or discomfort during surgical procedures. The global veterinary anesthesia equipment market is expected to grow from $0.57 billion in 2020 to $0.67 billion in 2021 at a compound annual growth rate (CAGR) of 17.5%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $0.88 billion in 2025 at a CAGR of 7.1%. Rising prevalence of oral diseases in dogs and cats is driving the market for veterinary anesthesia equipment used during oral examinations. Diagnosis and treatment of oral diseases, dental cleaning requires pet animals to be under general anesthesia as it is difficult to handle animals when they are awake and conscious. According to the American Veterinary Dental College, periodontal disease is the most common clinical condition occurring in adult dogs and cats. Thus, rising prevalence of oral diseases in pet animals is increasing the demand for veterinary anesthesia equipment driving market growth. The high prices of veterinary anesthetic equipment is acting as a restraint on the market. It is expensive for small veterinary hospitals and clinics to buy and maintain anesthesia equipment, thereby limiting market penetration. High price of the equipment can be attributed to advanced technology used in the equipment. Manufacturers of veterinary anesthesia equipment are introducing products with advanced features to provide safe and reliable treatment. The new products being introduced offer solutions to problems like power failure, battery failure or exhaustion and failure of electronic components. Companies such as DRE veterinary and Supera have been investing in introducing anesthetic machines with safety features. Manufacturers of veterinary anesthesia equipment are required to adhere to stringent regulations set by various regulatory bodies. For instance, the US Food and Drug Administration’s (FDA) Center for Veterinary Medicine (CVM) regulates the market for veterinary devices in the USA. The FDA issues guidelines with respect to manufacturing, procuring, packaging, branding, selling and usage of medical devices. Also, the FDA encourages veterinarians and pet owners to report defects in veterinary medical equipment. Major players in the market are JD medical, Midmark Corporation, Smiths medical, Mindray Medical and Kent Scientific. The countries covered in the global veterinary anesthesia equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, Australia. The regions covered in the global veterinary anesthesia equipment market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global veterinary anesthesia equipment market is segmented - 1) By Type: Standalone Anaesthesia Machines, Portable Anaesthesia Machines 2) By End User: Veterinary Hospitals, veterinary Clinics, Emergency Service Centres, Veterinary Homecare Settings 3) By Animal Type: Small, Large

The veterinary patient monitoring equipment market consists of sale of veterinary patient monitoring equipment which are used to monitor animal's respiration, blood pressure, and other vital signs. Veterinary patient monitoring equipment are used to monitor the animals to detect diseases at early stages to prevent any risks. Veterinary patient monitoring equipment industry includes companies that manufacture monitoring devices to detect diseases which affect animals The global veterinary patient monitoring equipment market is expected to grow from $0.33 billion in 2020 to $0.38 billion in 2021 at a compound annual growth rate (CAGR) of 15.2%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $0.46 billion in 2025 at a CAGR of 4.9%. Increase in the prevalence rate of diseases among animals serves as one of the major drivers for the veterinary patient monitoring equipment market. Increase in the incidence of diseases in livestock and companion animals will require monitoring equipment to diagnose the diseases among animals. For instance, according to the Banfield Pet Hospital's 2020 Veterinary Emerging Topics (VET) Report, more than 50% of the dogs at 1,000 hospitals in 2019 were overweight or obese. Overweight pets are more likely to suffer from joint disease, respiratory disease, and other preventable conditions. The increase in prevalence rate of diseases for animals results in increases demand for enhanced veterinary patient monitoring equipment. The veterinary patient monitoring equipment is highly expensive. The price of an equipment will be the significant expense for a veterinary clinic or hospital. For instance, price of average wearable devices ranges from $50 to $100 and will likely have a recurring software as a service (SaaS) fee to store & retrieve an animal’s health data analytics. These expenses hinder the growth of the veterinary patient monitoring equipment market. Veterinarians and pet or cattle owners are shifting to wearable technology to keep track of the animal behavior. Wearable technology are smart electronic devices that are worn on the body or integrated in the clothing or accessories and monitor body temperature, behavior and movement. These wearable monitoring devices provide timely insights regarding the overall health of the animal and help veterinarian to provide appropriate diagnosis to the animal. For instance, Vetrax, a wearable sensor worn on a dog’s collar, enables clinicians and pet owners to monitor aspects of an animal’s behavior when they are unsupervised. According to a report by Veterinary Practice News, 83% of pet owners are satisfied with the use of wearable technology and 68% are finding it an effective way of monitoring weight and diabetes of their pets. The veterinary patient monitoring equipment market is regulated by government agencies such as European Medicines Agency (EMA), USFDA (the US food and drug ministration), and others. EMA should certify the medical devices before they are marketed. EMA verifies the safety and quality of the devices before they can be certified and approved for use throughout the European Union. The EMA requires all the devices to comply with the regulations stated under Directive 2001/82/EC and Regulation (EC) No 726/2004. American pharmaceutical company Merck & Co. headquartered at New Jersey, acquired Antelliq in April 2019 for $2.4 billion. Antelliq will now work in Merck's animal health division. This acquisition marks the beginning of the trend for pharmaceutical companies to give equal importance to their veterinary devices as well as their human healthcare equipment. Antelliq, a company in the field of animal identification and monitoring will not only re-establish and widely improve Merck's reach in the veterinary monitoring devices market but it will also enhance the quality of the devices. Antelliq is an American company established in 2013 and is headquartered in Dallas, Texas. Major players in the market are Smiths Group plc, Hallowell Engineering & Manufacturing Corporation, DRE Veterinary, Digicare Biomedical Technology Inc. and Midmark Corporation. The countries covered in the global veterinary patient monitoring equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, Australia. The regions covered in the global veterinary patient monitoring equipment market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global veterinary patient monitoring equipment market is segmented - 1) By Product: Cardiac Monitoring Devices, Respiratory Monitoring Devices, Remote Patient Monitoring Devices, Multi-Parameter Monitoring Devices, Neuromonitoring Devices, Others 2) By End User: Veterinary Hospitals, Veterinary Clinics, Veterinary Research Centers 3) By Animal: Small Companion Animals, Large Companion Animals, Wild Animals, Zoo Animals, Aquatic Animals, Exotic Animals

The veterinary diagnostic equipment market consists of sales of veterinary diagnostic equipment and related services. Veterinary diagnostic equipment assists the veterinary practitioners in determining and identifying various disorders in animals. Veterinary diagnostic equipment industry includes companies that manufacture diagnostic equipment such as clinical thermometers, diagnostic lights, X-ray equipment, and certain diagnostic test kits. The global veterinary diagnostic equipment market is expected to grow from $0.74 billion in 2020 to $0.88 billion in 2021 at a compound annual growth rate (CAGR) of 18.9%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $1.13 billion in 2025 at a CAGR of 6.5%. Increase in the prevalence rate of diseases among animals serves as one of the major drivers of the veterinary diagnostic equipment market. Due to increase in the incidence of diseases in livestock and pets, the demand for enhanced diagnostic equipment increases. For instance, according to the Banfield Pet Hospital's 2020 Veterinary Emerging Topics (VET) Report, more than 50% of the dogs at 1,000 hospitals in 2019 were overweight or obese. Overweight pets are more likely to suffer from joint disease, respiratory disease, and other preventable conditions. The increase in prevalence rate of diseases in animals, results in increase in demand for diagnostic equipment, driving the veterinary diagnostic equipment market. The veterinary diagnostic equipment is highly expensive. The price of an equipment will be the significant expense for a veterinary clinic or hospital. To run a test center with blood testing machines, physiological monitors such as ECGs, anesthetic monitors etc., diagnostic imaging technology such as x-rays, ultrasound and MRI scanners, is highly capital intensive. Some kind of veterinary diagnostic equipment may be available on a budget, but with less precise diagnoses and thus less efficient treatments with less beneficial results. The high price of equipment hinders the growth of the veterinary diagnostic equipment market. Veterinary diagnostic equipment manufacturers are introducing advanced technologies such as advance blood micro sampling techniques to enable enhanced precision, patient-centered specimen collection and diagnosis of diseases in animals. Blood micro sampling is a technique that allows the participants to draw blood samples from their livestock and companion animals with ease. The samples are then forwarded to labs for further diagnosis. This technique is an extension to dry blood sampling, which is a method of collecting blood. For instance, Neoteryx launched the '3Rs-compliant Mitra' micro sampling device that works on the principle of micro sampling. The device uses Neoteryx's trademark Volumetric Absorptive Micro Sampling (VAMS) technology to facilitate more convenient and accurate remote sampling. Other companies investing in the trend of micro sampling includes Diatron with its Diatron aquila hematology analyzer. The US Food and Drug Administration (FDA) defines regulations for veterinary diagnosis equipment and can take appropriate action if a veterinary equipment is found misbranded or adulterated. The conditions for misbranding a diagnostic equipment is listed under title 21 and set by the Food and Drugs administration (FDA). For instance, as per the regulations under title 21, U.S code 352(f)(1), any veterinary medical equipment is considered misbranded if the labelling on the equipment is indefinite or unclear. Whereas, 21 U.S.C. 352(j) states that a veterinary medical equipment is considered misbranded if it is dangerous to the animal even when it is used in the manner recommended, or suggested as per the label. In May 2018, Zoetis Inc., US-based leading animal health company which discovers, develops, manufactures and markets veterinary vaccines and medicines, acquired Abaxis, Inc. for $2.0 Billion. With this acquisition Zoetis enhances its presence in the veterinary diagnostics market by utilizing the already established global network of Abaxis and increasing its revenue. This deal will help Zoetis achieve their goal of establishing sale of devices to more than 100 countries by using Abaxis's well-established diagnostic instruments and consumables. Abaxis, Inc. is a US-based firm that holds a strong product portfolio with various veterinary diagnostic instruments and kits. Major players in the market are IDEXX Laboratories, ABAXIS, HESKA Corporation, Zoetis and Virbac. The countries covered in the global veterinary diagnostic equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, Australia. The regions covered in the global veterinary diagnostic equipment market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global veterinary diagnostic equipment market is segmented - 1) By Product: Hematology, Immunodiagnostics, Clinical Chemistry, Molecular Testing 2) By End Users: Hospitals & Clinics, Reference Laboratories, Universities/Research Centers, Point-of-Care/In-House Testing 3) By Animal: Livestock Cattle, Domestic Pets

The veterinary vaccines market consists of sales of vaccines and related services which are used for the treatment and prevention of diseases in animals. These veterinary vaccines reduce animal suffering and transmission of microorganisms in the animal population. Veterinary vaccines are used to enhance the immunity power of animals by improving the animal health, which also prevents transmission of diseases from animals to humans. Veterinary vaccines industry includes entities that produce veterinary vaccines like livestock vaccines and companion animal vaccines. The global veterinary vaccines market is expected to grow from $7 billion in 2020 to $7.73 billion in 2021 at a compound annual growth rate (CAGR) of 10.4%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $10.18 billion in 2025 at a CAGR of 7.1%. The increase in the number of animals suffering from range of diseases is increasing the demand for vaccines to prevent and treat such diseases, thus driving the veterinary vaccines market According to the estimates from report by Animal and Plant Health Agency, a total of 3289 number of new TB herd incidents were detected in England Bovine tuberculosis is a chronic disease that usually affects animals such as cattle, but it can affect all mammals causing a general state of illness, coughing and eventually lead to death. However, the disease can be treated with specific antibiotics that kills the TB bacteria. This rising prevalence of diseases in animals is expected to drive the veterinary vaccines market during the forecast period. High storage costs are acting as a major restraint for the growth of the veterinary vaccine market. Improper storage conditions and delay in the shipping can cause vaccines to lose their desired immune properties. For example, during transportation, vaccines can undergo biodegradation, if they are not transported within the required temperature limits. Thus, special care is required for the transportation of the vaccines in order to maintain the efficiency of the vaccines, which increases the storage and transportation cost for the vaccines. According to report published by National Institute of Standards and Technology (NIST), approximately 35% of vaccines lost their potencies during the shipment, as they were stored at abnormal temperatures. Thus, high storage costs for vaccines are expected to result in additional costs for manufacturing companies and limit the growth of the market. Companies in the veterinary vaccines market are increasingly looking for strategic partnerships and collaborations to enter into new geographies and to share the Research & Development projects. For example, in 2020, the Pirbright Institute, a UK based animal disease research institute, partnered with ECO Animal Health, a UK based Pharmaceutical company, and the Vaccine Group (TVG) to develop porcine respiratory and reproductive syndrome virus (PRRSV) vaccines. The vaccine group is a biotechnology company that develops animal vaccines and is based in Plymouth, UK Similarly, MSD Animal Health, a division of Merck & Co with headquarters in the US, made a strategic partnership with Vinovo. This partnership will help MSD Animal Health to combine its unique broad vaccine product line and Vinovo’s vaccine delivery system to vaccination process, thus improving bird welfare, and reducing vaccine reactions. Also,Wageningen bio veterinary research made a strategic alliance Ceva with headquarters in Switzerland, to improve their Research on the global threat of emerging and reemerging diseases for animals. The veterinary vaccines market is regulated by authorities such as European Medical Agency and the US Center for Veterinary Biologics. For instance, veterinary vaccine companies in Europe are required to adhere to European technical requirements mentioned in Annex 1, Title II, to Directive 2001/82/EC, as amended by Directive 2009/9/EC, and the European Pharmacopoeia (Ph. Eur.). According to these regulations, veterinary vaccines are required to undergo safety test before getting the approval, where vaccines are classified into activated vaccines and inactivated Vaccines. In activated vaccines, each batch of vaccines should have a dose that is double the standard dose. In inactivated vaccines, each batch of vaccines should be ten times the standard dose for the active vaccines. Activated vaccines are usually tested by in vitro titration, while serological tests are commonly used for inactivated vaccines. Major players in the market are Boehringer Ingelheim GmbH, Merck Animal Health, Zoetis Inc., Eli Lilly and Company, and Bayer AG (Bayer Animal Health). The countries covered in the global veterinary vaccines market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, Australia. The regions covered in the global veterinary vaccines market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global veterinary vaccines market is segmented - 1) By Application: Livestock Vaccines, Companion Animal Vaccines 2) By Vaccine Type: Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Others 3) By Disease Type: Anaplasmosis, Canine Parvovirus, Foot & Mouth Disease, Newcastle Disease, Distemper Disease, Influenza, Porcine Reproductive & Respiratory Syndrome (PRRS)

The veterinary parasiticides market consists of sales of veterinary parasiticides and related services which are used in the treatment of parasitic diseases in livestock, pets, and other animals. Veterinary parasiticides industry includes establishments that produce a cure to parasitic diseases that can be caused by helminths, amoeba, ectoparasites, parasitic fungi, and protozoa. The veterinary parasiticides are chemical substances that destroy or inhibit micro-organisms or parasites and improves the animals’ health. The global veterinary parasiticides market is expected to grow from $4.48 billion in 2020 to $4.98 billion in 2021 at a compound annual growth rate (CAGR) of 11.2%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $6.63 billion in 2025 at a CAGR of 7.4%. The animals are increasingly being affected by zoonotic pathogens which are the leading cause for foodborne diseases worldwide. Zoonotic diseases are infectious diseases caused by bacteria, viruses and parasites, especially Salmonella and Campylobacter, which can be transmitted directly or indirectly between animals and humans. These diseases get passed through the food chain to humans which is a potential threat and creating a dire need to prevent such diseases among animals., According to the FDA in 2020, about 128,000 hospitalizations and 3,000 deaths were reported in America due to foodborne illness. The necessity to curb these infections in animals drives the market for veterinary parasiticides. Lack of awareness about animal diseases due to limited information on microbes and their impact on wildlife and livestock disease restrains the veterinary parasiticides industry. Lack of awareness about the occurrence of zoonotic diseases and their impact on public health is a major hurdle for the animal parasiticides market. This lack of awareness does not allow people to adopt the parasiticides for livestock/wildlife which not only control different parasitic diseases but also improve animal health. For instance, Proceedings of the National Academy of Sciences (PNAS) reported that only ten diseases account for around 50% of all published knowledge on diseases at the wildlife-livestock interface and the analysis was based on almost 16,000 publications from last century. The lack of knowledge and awareness will restrain the growth of the market. Chewable tablets are being used to prevent animals from being affected by ticks, worms, fleas and others. Treatments with these tablets are easier to administer. The chewable tablets are available in either a beef-flavored tablet or soft chew. For instance, the IVERHART MAX chewable tablets protect dogs from the 4 most common worms: heartworms (infection caused by bite of an infected mosquito), roundworms, hookworms (affects the intestines) and tapeworms (caused by ingesting an infected flea). Such advances in technology are significantly driving the veterinary parasiticides industry. The veterinary parasiticides market is regulated by government agencies such as European Medicines Agency (EMA), USFDA (the US food and drug ministration), and others. For instance, under the directive 2008/97/EC of the European Parliament certain products/drugs which contain substances having a hormonal or thyrostatic action and beta agonists are banned. Meat or products from food producing animals which have an oestrogenic, androgenic or gestagenic action or beta-agonists are prohibited for human consumption unless those animals have been treated with veterinary medicines complying with the requirements of Article 6 of Council Directive 96/22/EC. Major players in the market are Bayer AG (Germany), Zoetis (U.S.), Boehringer Ingelheim (Germany), Merck (U.S.) and Eli Lilly and Company (U.S.). The countries covered in the global veterinary parasiticides market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, Australia. The regions covered in the global veterinary parasiticides market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global veterinary parasiticides market is segmented - 1) By Type: Endoparasiticides, Ectoparasiticides, Endectocides 2) By End Users: R&D facilities, Farms, Veterinary Clinics 3) By Product: Oral Liquids, Tablets, Injectables, Sprays, Others 4) By Application: Farm Animals, Companion Animals

The orthopedic prosthetics market consists of sales of orthopedic prosthetic devices. Orthopedic prosthetics are artificial devices used to replace a missing body part lost due to disease, trauma, surgical removal of body appendage, disabling illness or congenital conditions. Orthopedic prosthetic devices are segmented into upper and lower extremity prosthetics. Upper extremity prosthetics include hand, elbow, shoulder and lower extremity prosthetics include foot and ankle, knee, hip. The global orthopedic prosthetics market is expected to grow from $1.75 billion in 2020 to $1.95 billion in 2021 at a compound annual growth rate (CAGR) of 11.4%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $2.53 billion in 2025 at a CAGR of 6.7%. The orthopedic prosthetics market is being driven by an increasing number of trauma cases and accidental injuries. The trauma cases and accidental injuries are caused by various factors such as road accidents, sports injuries, other medical complications and work related accidents. Most of these injuries may require amputations and prosthetic devices to replace the lost body part. For instance, as of 2017 there are 2.1 million people living with limb loss in the USA and about 300-500 amputations were performed each day. Therefore, driving the demand for orthopedic prosthetics, thus growth in the orthopedic prosthetics market. The orthopedic prosthetics market is being restrained by entry barriers due to guidelines by the FDA's regulatory control over these devices based on the risks associated with them. These devices fall into the class III category as per the FDA, which includes devices involving high risk associated with the usage. Class III devices are required to undergo a premarket approval application (PMA), which is the FDA process of scientific evaluation for assessing the safety of these devices. Such stringent guidelines associated with these devices are creating an entry barrier and thus restraining the orthopedic prosthetics market. For instance, DePuy's hip prosthetic device was denied approval by the FDA after it was assessed as unsafe, thus creating an entry barrier and restraining the market. The companies in the orthopedic prosthetics market are witnessing the emergence of 3D printed orthopedic prosthetics. 3D printing is a process which involves a digital model being transformed into a three dimensional solid object. 3D printed orthopedic prosthetics are devices that are manufactured by the process of 3D printing. These devices have shorter lead times, lower costs and consistent quality. For instance, Zdravprint is a Russian company which is developing prosthetics for hand, elbow and shoulder using 3D printing technology. The orthopedic prosthetics market is regulated as per the guidelines by the food and drug administration (FDA). The FDA has subjected these devices under the class III category, which includes those devices involving a high risk associated with the usage. Class III devices are required to undergo a premarket approval application (PMA) before they can be used. PMA is the process followed by the FDA for scientific evaluation, to assess the safety of the devices. If a PMA application is found to be lacking valid clinical assessment and correct scientific reasoning, it impacts the FDA's approval and prevents the prosthetic device from being released into the market. In June 2019, Smith & Nephew acquired orthopedic joint reconstruction business from Brainlab for an undisclosed amount. With this acquisition the company expands its business of shoulder and wrist implants. The Brainlab orthopaedic joint reconstruction business provides surgeons with digital workflow tools, from pre-operative planning to intraoperative navigation to postoperative evaluation and sharing. Major players in the market are Otto Bock HealthCare GmbH, Blatchford Ltd, Zimmer Biomet Inc., DePuy Synthes, Stryker Corp. The countries covered in the global orthopedic prosthetics market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, Australia. The regions covered in the global orthopedic prosthetics market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The global orthopedic prosthetics market is segmented - 1) By Product Type: Upper Extremity Prosthetics, Lower Extremity Prosthetics, Sockets, Other Products 2) By End Users: Hospitals, Prosthetic Clinics, Rehabilitation Center, Others 3) By Technology: Conventional Orthopedic Prosthetics, Electric-powered Orthopedic Prosthetics, Hybrid Orthopedic Prosthetics